...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Medical Microbiology: An Official Journal of the Pathological Society of Great Britain and Ireland >Impact of different SARS-CoV-2 assays on laboratory turnaround time
【24h】

Impact of different SARS-CoV-2 assays on laboratory turnaround time

机译：不同SARS-COV-2测定对实验室周转时间的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction Clinical microbiology laboratories have had to cope with an increase in the volume of tests due to the emergence of the SARS-CoV-2 virus. Short turnaround times (TATs) are important for case tracing and to help clinicians in patient management. In such a context, high-throughput systems are essential to process the bulk of the tests. Rapid tests are also required to ensure shorter TATs for urgent situations. In our laboratory, SARS-CoV-2 assays were initially implemented on our custom platform using a previously published method. The commercial cobas 6800 (Roche diagnostics) assay and the GeneXpert Xpress (Cepheid) SARS-CoV-2 assay were implemented on 24 March and 8 April 2020, respectively, as soon as available. Hypothesis/Gap Statement Despite the abundant literature on SARS-CoV-2 assays, the articles focus mainly on the diagnostic performances. This is to our knowledge the first article that specifically studies the TAT of different assays. Aim We aimed to describe the impact of various SARS-CoV-2 assays on the TAT at the beginning of the outbreak. Methodology In this study, we retrospectively analysed the TAT of all SARS-CoV-2 assays performed in our centre between 24 February and 9 June, 2020. Results We retrieved 33?900 analyses, with a median TAT of 6.25?h. TATs were highest (6.9?h) when only our custom platform was used (24 February to 24 March, 2020). They were reduced to 6.1?h when the cobas system was introduced (24 March to 8 April, 2020). The implementation of the GeneXpert further reduced the median TAT to 4.8?h (8 April to 9 June, 2020). The GeneXpert system had the shortest median TAT (1.9?h), followed by the cobas (5.5?h) and by our custom platform (6.9?h). Conclusion This work shows that the combination of high-throughput systems and rapid tests allows the efficient processing of a large number of tests with a short TAT. In addition, the use of a custom platform allowed the quick implementation of an in-house test when commercial assays were not yet available.
机译：由于SARS-COV-2病毒的出现，临床微生物学实验室必须应对试验量的增加。短期周转时间（TATS）对于案例跟踪很重要，并帮助患者管理中的临床医生。在这种情况下，高吞吐量系统对于处理大量测试是必不可少的。还需要快速测试以确保较短的TATS用于紧急情况。在我们的实验室中，SARS-COV-2测定最初在我们的定制平台上使用先前发布的方法在我们的定制平台上实施。商业COBAS 6800（ROCHE诊断）测定和Genexpert Xpress（Cepheid）SARS-COV-2分别在2020年4月24日和4月8日，分别实施。假设/差距声明尽管SARS-COV-2测定的文献丰富，但物品主要关注诊断表现。这是我们了解的第一篇文章，专门研究不同的测定的TAT。目的是为了描述爆发开始时各种SARS-COV-2测定对TAT的影响。在本研究中的方法论，我们回顾性地分析了在2月24日和9日至6月24日至6月24日之间进行的所有SARS-COV-2测定的TAT。结果我们检索了33？900分析，中位数为6.25？H。当仅使用我们的定制平台时，TATS最高（6.9？H）（2月2日至3月24日2020年3月24日）。当胶带系统引入COBAS系统（3月8日至4月8日）时，它们减少到6.1？H. Genexpert的实施进一步将中位数减少到4.8（4月8日至6月9日）。 Genexpert系统具有最短的中位数TAT（1.9？H），其次是COBAS（5.5？H）和我们的定制平台（6.9？H）。结论这项工作表明，高通量系统和快速测试的组合允许有效地处理具有短TAT的大量测试。此外，当商业测定尚未使用时，使用自定义平台允许快速实施内部测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号